130 related articles for article (PubMed ID: 10098667)
21. Design, Synthesis, and Evaluation of Novel Prodrugs of Transition State Inhibitors of Norovirus 3CL Protease.
Galasiti Kankanamalage AC; Kim Y; Rathnayake AD; Alliston KR; Butler MM; Cardinale SC; Bowlin TL; Groutas WC; Chang KO
J Med Chem; 2017 Jul; 60(14):6239-6248. PubMed ID: 28671827
[TBL] [Abstract][Full Text] [Related]
22. Novel aza peptide inhibitors and active-site probes of papain-family cysteine proteases.
Verhelst SH; Witte MD; Arastu-Kapur S; Fonovic M; Bogyo M
Chembiochem; 2006 Jun; 7(6):943-50. PubMed ID: 16607671
[TBL] [Abstract][Full Text] [Related]
23. A general solid phase method for the preparation of diverse azapeptide probes directed against cysteine proteases.
Kato D; Verhelst SH; Sexton KB; Bogyo M
Org Lett; 2005 Dec; 7(25):5649-52. PubMed ID: 16321013
[TBL] [Abstract][Full Text] [Related]
24. Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements.
Webber SE; Okano K; Little TL; Reich SH; Xin Y; Fuhrman SA; Matthews DA; Love RA; Hendrickson TF; Patick AK; Meador JW; Ferre RA; Brown EL; Ford CE; Binford SL; Worland ST
J Med Chem; 1998 Jul; 41(15):2786-805. PubMed ID: 9667969
[TBL] [Abstract][Full Text] [Related]
25. Structure-activity relationships of heteroaromatic esters as human rhinovirus 3C protease inhibitors.
Im I; Lee ES; Choi SJ; Lee JY; Kim YC
Bioorg Med Chem Lett; 2009 Jul; 19(13):3632-6. PubMed ID: 19464175
[TBL] [Abstract][Full Text] [Related]
26. Optimize the interactions at S4 with efficient inhibitors targeting 3C proteinase from enterovirus 71.
Zhang L; Huang G; Cai Q; Zhao C; Tang L; Ren H; Li P; Li N; Huang J; Chen X; Guan Y; You H; Chen S; Li J; Lin T
J Mol Recognit; 2016 Nov; 29(11):520-527. PubMed ID: 27185390
[TBL] [Abstract][Full Text] [Related]
27. Design and synthesis of irreversible depsipeptidyl human rhinovirus 3C protease inhibitors.
Webber SE; Marakovits JT; Dragovich PS; Prins TJ; Zhou R; Fuhrman SA; Patick AK; Matthews DA; Lee CA; Srinivasan B; Moran T; Ford CE; Brothers MA; Harr JE; Meador JW; Ferre RA; Worland ST
Bioorg Med Chem Lett; 2001 Oct; 11(20):2683-6. PubMed ID: 11591501
[TBL] [Abstract][Full Text] [Related]
28. NMR solution structures of the apo and peptide-inhibited human rhinovirus 3C protease (Serotype 14): structural and dynamic comparison.
Bjorndahl TC; Andrew LC; Semenchenko V; Wishart DS
Biochemistry; 2007 Nov; 46(45):12945-58. PubMed ID: 17944485
[TBL] [Abstract][Full Text] [Related]
29. Hydrolysis of a series of synthetic peptide substrates by the human rhinovirus 14 3C proteinase, cloned and expressed in Escherichia coli.
Orr DC; Long AC; Kay J; Dunn BM; Cameron JM
J Gen Virol; 1989 Nov; 70 ( Pt 11)():2931-42. PubMed ID: 2555433
[TBL] [Abstract][Full Text] [Related]
30. A continuous colorimetric assay for rhinovirus-14 3C protease using peptide p-nitroanilides as substrates.
Wang QM; Johnson RB; Cox GA; Villarreal EC; Loncharich RJ
Anal Biochem; 1997 Oct; 252(2):238-45. PubMed ID: 9344409
[TBL] [Abstract][Full Text] [Related]
31. Design and synthesis of protein-protein interaction mimics as Plasmodium falciparum cysteine protease, falcipain-2 inhibitors.
Rizzi L; Sundararaman S; Cendic K; Vaiana N; Korde R; Sinha D; Mohmmed A; Malhotra P; Romeo S
Eur J Med Chem; 2011 Jun; 46(6):2083-90. PubMed ID: 21429631
[TBL] [Abstract][Full Text] [Related]
32. New peptidic cysteine protease inhibitors derived from the electrophilic alpha-amino acid aziridine-2,3-dicarboxylic acid.
Schirmeister T
J Med Chem; 1999 Feb; 42(4):560-72. PubMed ID: 10052963
[TBL] [Abstract][Full Text] [Related]
33. Development of synthetic peptide substrates for the poliovirus 3C proteinase.
Weidner JR; Dunn BM
Arch Biochem Biophys; 1991 May; 286(2):402-8. PubMed ID: 1654789
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of dipeptidyl alpha',beta'-epoxy ketones, potent irreversible inhibitors of the cysteine protease cruzain.
Roush WR; González FV; McKerrow JH; Hansell E
Bioorg Med Chem Lett; 1998 Oct; 8(19):2809-12. PubMed ID: 9873627
[TBL] [Abstract][Full Text] [Related]
35. Recent advances in the synthesis, design and selection of cysteine protease inhibitors.
Hernandez AA; Roush WR
Curr Opin Chem Biol; 2002 Aug; 6(4):459-65. PubMed ID: 12133721
[TBL] [Abstract][Full Text] [Related]
36. Aza-peptide epoxides: a new class of inhibitors selective for clan CD cysteine proteases.
Asgian JL; James KE; Li ZZ; Carter W; Barrett AJ; Mikolajczyk J; Salvesen GS; Powers JC
J Med Chem; 2002 Nov; 45(23):4958-60. PubMed ID: 12408706
[TBL] [Abstract][Full Text] [Related]
37. Cysteine protease inhibition by azapeptide esters.
Magrath J; Abeles RH
J Med Chem; 1992 Nov; 35(23):4279-83. PubMed ID: 1447732
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis and biological evaluation of peptidyl-vinylaminophosphonates as novel cysteine protease inhibitors.
Bhattacharya AK; Rana KC
Bioorg Med Chem; 2011 Dec; 19(23):7129-35. PubMed ID: 22019466
[TBL] [Abstract][Full Text] [Related]
39. Proteasome inhibitors.
Reboud-Ravaux M
Prog Mol Subcell Biol; 2002; 29():110-25. PubMed ID: 11908069
[No Abstract] [Full Text] [Related]
40. Expression and purification of recombinant rhinovirus 14 3CD proteinase and its comparison to the 3C proteinase.
Davis GJ; Wang QM; Cox GA; Johnson RB; Wakulchik M; Dotson CA; Villarreal EC
Arch Biochem Biophys; 1997 Oct; 346(1):125-30. PubMed ID: 9328292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
